Influenza A viruses are significant human pathogens, both in their sporadic pandemic and endemic (seasonal) forms. Antiviral therapies are commonly used to treat both severe illness in high-risk patients and self-limited influenza infection. Widespread emergence of antiviral resistance among seasonal influenza A viruses began during the 2004-2005 influenza season, when a significant increase in the prevalence of adamantane resistance among H3N2 influenza viruses was observed [1, 2] . In most cases, a single amino acid substitution in the M2 protein (S31N) was responsible for this resistance, having no effect on viral fitness [3, 4] . During the subsequent season in 2005-2006, H3N2 adamantane resistance surpassed 90%, rendering this class of drugs ineffective as a viable treatment for seasonal H3N2 influenza infections [3] .
By the time H3N2 adamantane resistance became prominent, a shift in practice was already occurring for a number of reasons, and despite seasonal H1N1 strains remaining adamantane susceptible, use of these drugs decreased and the neuraminidase inhibitors (NAIs), particularly oseltamivir, became the primary influenza antiviral of choice. Widespread resistance to oseltamivir was deemed unlikely because NAIs closely resemble the sialic acids that are the natural substrates for the neuraminidase's active site [5] , and that any mutation leading to resistance was expected to lead to reduced fitness of the virus [6, 7] .
When NAI resistance mutations were first identified through both in vitro selection under drug pressure and during oseltamivir treatment of experimentally infected individuals [8] [9] [10] , the neuraminidase (NA) changes at position 275, 292, and 119 identified in H3N2 and H1N1 viruses led to a significant reduction in the ability of the viruses to replicate and transmit in animal models [7, 9, 11, 12] . This correlated well with the low incidence of NAI resistance of 0.32% in the adult population observed during [2005] [2006] , when most circulating seasonal viruses retained susceptibility to oseltamivir [6] .
During 2007-2009, the unexpected emergence of a dominant clade of oseltamivir-resistant seasonal H1N1 virus demonstrated that NAI resistance could occur in the context of an otherwise fit and transmissible virus. By the end of the 2008-2009 influenza season, 98% of seasonal H1N1 isolates worldwide exhibited resistance to oseltamivir [13] . Recent studies have identified permissive changes in the NA of seasonal H1N1 that might account for the widespread circulation of oseltamivir-resistant strains [14] .
Over the past 4 years, a smaller number of NAI-resistant H3N2 viruses have been identified, some containing the H274Y change (equivalent mutation in N2 subtype NA) or other newly identified NA amino acid changes. In animal models, these resistant H3N2 viruses demonstrated equivalent fitness and transmissibility to wild-type viruses, suggesting that widespread seasonal H3N2 NAI resistance is also a threat [15] [16] [17] .
Recently, the 2009 pandemic H1N1 influenza virus emerged in Mexico and the southwestern United States [18, 19] and rapidly spread worldwide, causing increased morbidity and mortality among children and young adults throughout most of 2009 and early 2010. Similar to seasonal H3N2 viruses, the 2009 pandemic viruses are resistant to the adamantanes [20] , making NAIs the drug class of choice. The concern for increased levels of severe disease and need for a parenteral therapy for patients unable to achieve adequate NAI levels orally or via inhalation prompted the US Food and Drug Administration (FDA) to release a new parenteral NAI, peramivir, on an emergency use authorization for treatment of severe pandemic H1N1 infections.
After only a few months into the pandemic, reports of sporadic NAI resistance emerged, leading to the possibility of a virus with limited susceptibility to available antivirals transmitting in the community [21] [22] [23] . Recently, we isolated 2 adamantineresistant pandemic H1N1 viruses from 2 different immunocompromised patients and found that, after a period of 9-14 days of NAI treatment, the viruses from these patients independently acquired the NA H275Y mutation [23] . We further demonstrated that the H275Y change in these pandemic H1N1 viruses conferred resistance not only to oseltamivir, but also to peramivir, suggesting that for those at risk of severe disease with NAI resistant infections, intravenous peramivir may not be an adequate treatment option.
In this report, we characterized the multidrug-resistant pandemic influenza A(H1N1) viruses isolated from the 2 individuals described previously [23] , to determine how great a potential exists for widespread multidrug antiviral resistance and transmissibility. We examined their viral genomes for other significant amino acid substitutions and then evaluated the virulence, fitness, and transmissibility in a mammalian host with use of a ferret transmission model.
METHODS

Viruses
Viral isolates were collected from patients in an institutional review board-approved protocol (clinicaltrials.gov identifier: NCT00533182). and the patients from which these viruses were isolated have been previously described [23] . After 48 h, the other 4 groups were placed in contact with the inoculated ferrets by placing 2 naive ferrets in each cage with 2 inoculated ferrets. Daily weights, temperatures, nasal washes, and clinical scores were performed, as previously described [17] . Two ferrets from each of the inoculated groups were euthanized on day 4 after inoculation and on day 6 after inoculation (day 4 after exposure), 2 from each of the transmission groups were euthanized. On day 14 after inoculation (day 12 after exposure), all remaining animals were euthanized. Whole lungs, trachea, tracheobronchial lymph nodes, rostral nasal turbinates, and spleen were harvested. All animal experiments were performed following National Institutes of Health Institutional Animal Care and Use Committee-approved protocols and guidelines.
Quantification of Virus
Quantification of viral shedding in nasal washes was determined using 1-step real-time reverse-transcription polymerase chain reaction (RT-PCR) for the influenza A virus matrix 1 gene, as previously described [24] . Amplification and sequencing of the NA gene was performed on each viral isolate recovered to determine if the NA gene sequence remained stable after infection and transmission.
Lung tissues were weighed and homogenized in sterile cold Leibovitz's medium (Gibco L-15, Invitrogen) containing 1X penicillin, streptomycin, and amphotericin B (Gibco Anti-Anti, Invitrogen). Standard plaque assays were performed [25] . Titers are expressed as pfu per gram of tissue.
Sequence Analysis
RT-PCR and sequencing was performed on the primary viral isolates, as previously described [26] . Full-length sequences of each gene segment of the 4 viruses used to inoculate the ferrets were generated and deposited into GenBank (accession numbers HQ263267-HQ263294, GU571152-GU571156). The hemagglutinin (HA) and NA genes were amplified and sequenced from virus isolated from the ferret nasal washes. These sequences were compared with the sequences generated from the viral isolates used for inoculation.
Histopathological Analysis
Standard hematoxylin-and-eosin stains were performed for all tissues, and Brown and Hopps tissue Gram stain was applied to select sections. Immunohistochemistry was performed on all sections from ferrets euthanized on day 4, as previously described [27] .
RESULTS
Full Viral Genome Analysis
All 4 viruses used for inoculation were sequenced, and amino acid sequences of the deduced open reading frames were aligned. The wild-type viruses, A and B, differed in 4 of the gene segments by 8 amino acids (Table 1) . Virus A and NAI resistant virus Ar differed only by 2 nonsynonymous changes, coding for an H275Y mutation in NA and an L95I mutation in NS1. Viruses B and Br differed by 3 nonsynonymous changes, coding for A15T and F432L mutations in HA, and the H275Y mutation in NA (Table 1) . HA and NA gene sequences of viruses isolated from the ferret nasal washes contained sequences identical to those of the inoculating viruses.
Clinical Disease and Transmission
All ferrets inoculated with virus showed signs of clinical disease and weight loss 2 days after inoculation. Viruses A and Ar caused similar mean weight loss of 5%-10% ( Figure 1A ) and a mean clinical score of 1, with duration of clinical symptoms of 6-7 days ( Figure 2A ). Viruses B and Br caused a similar mean weight loss of 6% on day 2 and 6%-7% by the end of the study, but B demonstrated increased weight loss of 13% during the study ( Figure 1B ). Virus B and Br also showed no statistically significant difference in clinical score in the inoculated animals, with a mean score near 2 and duration of clinical symptoms of 7-10 days ( Figure 2B ).
All ferrets in each of the 4 contact transmission groups demonstrated clinical illness. The wild-type and resistant virus, viruses A and Ar, demonstrated similar mean peak weight loss of 10%-11% ( Figure 1A ). Clinical symptoms began 2 days after contact with infected animals, and duration of symptoms in both groups was .10 days. The clinical scores in both groups were similar until day 9, shortly after 1 ferret in the resistant virus group was found dead on day 6. Although the ferrets in the wild-type group exhibited a higher mean peak clinical score during days 9-14, no deaths occurred in this group (Figure 2A) .
Virus B and Br demonstrated nearly equivalent clinical scores, slightly higher than those seen with virus A and Ar, and similar in duration of disease ( Figure 2B ). Weight loss in both groups was also equivalent until day 9, after which virus B demonstrated increased weight loss including an animal found dead on day 12 ( Figure 1B ).
Viral Shedding and Lung Titers
No difference was observed between the wild-type and resistant viruses in initiation or duration of shedding in the inoculated groups. All ferrets inoculated with either the wild-type or resistant viruses demonstrated active viral shedding by day 2, and viral RNA was detectable for 5 days (Figure 3 ). Similar amounts of viral RNA were detected in the nasal washes of both the wild-type and resistant virus groups. Likewise, day 4 viral titers of lung tissue were equivalent in all 4 virus groups, reaching mean peak titers of 10 No virus was isolated from the lungs harvested on day 14. NOTE. Eight amino acid differences were observed between the 2 wild-type viruses, demonstrating that the viruses isolated from the 2 patients were not identical at baseline. The only shared mutation selected for under drug pressure between the resistant viral isolates was the NA H275Y mutation. 
Pathology
There were no discernible differences in gross pathology attributable to specific viruses or route of viral inoculation. Gross examination of the lungs varied in each ferret from no obvious gross pathology to occasionally severe, multifocal, bronchocentric, firm tan foci often accompanied by diffuse mild to moderate congestion. Tracheobronchial lymph nodes were enlarged and firm but normal in appearance on cut section. Examination of the upper respiratory tract revealed no gross findings except variable amounts of mucus within the nasal cavity or proximal trachea. Grossly all other organs were within normal limits except for the animal that was found dead on day 12. This animal was found to have a hemothorax, and its lungs were dark red with tan foci and partially atelectatic. Histopathological analysis of ferrets euthanized on day 4 and 14 demonstrated no significant differences between ferret groups attributable to a specific virus or route of inoculation. On day 4, some ferrets showed a mild neutrophilic and lymphocytic sinusitis with some submucosal gland involvement [ Figure 5 A], and all ferrets had a mild to moderate, multifocal, neutrophilic, and lymphohistiocytic laryngitis and sialadenitis, with similar inflammation in the overlying epithelium [ Figure 5 C]. A distal tracheitis was observed, and in some animals, similar changes extended throughout the entire trachea, with occasional foci of ulceration in the tracheal epithelium [ Figure 5 E, G] .
Immunohistochemistry of the rostral nasal cavity, larynx, and trachea of animals euthanized on day 4 revealed influenza viral antigen labeling in the acinar cells of the submucosal glands and in pseudostratified respiratory epithelium, most frequently in goblet cells, but also in the squamous epithelium of the nasal cavity [ Figure 5 B, D, F, H-I ]. There was also significant labeling of esophageal submucosal glands, although no inflammation of these glands was observed.
An acute bronchointerstitial pneumonia was present in peripheral and medial sections of the right lung lobes of all ferrets euthanized at day 4. This was characterized by diffuse, occasionally severe, lymphohistiocytic necrotizing bronchiolitis accompanied by multifocal, coalescing lymphohistiocytic and neutrophilic alveolitis with multifocal type II pneumocyte hyperplasia [ Figure 5 J-K, N, P] . Similar inflammation was also seen in bronchi. Lymphoplasmacytic aggregates were common both perivascularly and peribronchially and were seen scattered subpleural and in the pulmonary parenchyma. Influenza viral antigen distribution in the lungs was in both the epithelium and submucosal glands of the bronchi and bronchioles and was present in alveolar duct epithelium, type I and type II alveolar epithelial cells, and alveolar macrophages [ Figure 5 L-M, O, Q-R]. The degree and distribution of labeling correlated closely with the degree of inflammation. Histopathology of the enlarged tracheobronchial lymph nodes revealed a pattern consistent with reactive lymph nodes.
In the animals euthanized on day 14, the typical histopathologic pattern seen was an upper respiratory tract in normal limits and a resolving bronchointerstitial pneumonia characterized by mild, multifocal, lymphohistiocytic bronchiolitis with occasional extension of this inflammation in adjacent alveolar ducts and alveoli [ Figure 6 A]. In addition, scattered foci of interstitial fibrosis were located adjacent to bronchi and bronchioles, intrapulmonary parenchymal lymphoplasmacytic aggregates, and mild to moderate congestion and edema. One ferret euthanized at day 14 had a focus of bronchiolitis obliterans with organizing pneumonia characterized by replacement of alveolar architecture by fibrosis [ Figure 6 B], as previously described in ferrets infected with a classical swine influenza virus [27] .
The animal that died on day 6 had no notable histopathologic changes other than those seen in the animals that survived, and no specific cause of death was determined. Histopathologic analysis of the animal that died with a hemothorax on day 12 revealed coalescing hemorrhage and edema and acute, suppurative bronchopneumonia that obliterated the underlying pulmonary architecture [ Figure 6 C-D]. These changes overlaid the viral pneumonia pattern already described in the day 4 ferrets. Bronchopneumonia were present in myriads of gram-positive short bacilli, morphologically consistent with Listeria monocytogenes [ Figure 6 E-H].
DISCUSSION
This study illustrates that naturally occurring NAI-resistant pandemic H1N1 influenza mutants retain replicative fitness, transmissibility, and virulence in the ferret model. These multidrug-resistant viruses isolated after just 9-14 days of NAI therapy from immunocompromised patients are resistant to the adamantanes, oseltamivir, and peramivir and maintain their ability to cause significant disease in a relevant animal model.
An analysis of the full genome of these viruses demonstrates that amino acid changes can be selected for rapidly in multiple genes of the virus during a single infection, occurring rapidly in the 2 cases described [23] . Viruses A and B differed at 8 amino acid positions in their genome when first isolated, but most were previously reported polymorphisms seen in 2009 pandemic H1N1 influenza viruses. After a short period of NAI treatment of the host, both viruses isolated, virus Ar and Br, contained the NA H275Y change as the dominant genotype.
It is unclear whether the small number of other changes that were seen in each virus after selection under drug pressure play any role in the maintenance of virulence and transmissibility. The H275Y change was the only common change observed under drug pressure. The H275Y change was maintained during the infection and transmission experiment, with no other amino acid changes or reversion occurring, demonstrating that the H275Y was stable even without drug pressure. This strongly suggests that these pandemic H1N1 viruses were able to accommodate the single H275Y change conferring multi-NAI resistance without requiring any other NA changes to maintain virulence and transmissibility, unlike recent oseltamivirresistant seasonal H1N1 influenza viruses [14] .
The clinical disease caused by both resistant viruses containing the H275Y was similar to that induced by the initial wildtype isolates. In the case of viruses A and Ar, slightly more severe disease was noted in the resistant virus-infected groups characterized by higher weight loss and 1 spontaneous death, but clinical score and duration of symptoms were very similar and, in some cases, were slightly lower than those in the wild-type groups. The opposite was noted with virus B and Br, with more weight loss and 1 death occurring in the wild-type infected groups, but duration of symptoms and clinical scores generally higher in the resistant virus-infected groups. These data demonstrate that no single measure can easily describe the extent of clinical disease, suggesting that a summation of data including weight loss, duration of illness, clinical score, and pathological changes more accurately reflects the overall disease in these animals. With this in mind, it is clear that despite the small differences described, the overall clinical disease caused by each of the resistant and wild-type viruses in this study is similar.
We noted nearly identical duration of shedding between wildtype and resistant virus groups and no significant difference in amounts of viral RNA detected at each time point. The quantity of virus isolated from the lungs on day 4 was also similar between groups, demonstrating that the resistant viruses maintain their ability to replicate in both the upper and the lower respiratory tract. A difference was seen between those ferrets inoculated intranasally and those who contracted influenza by transmission. In the latter groups, a higher level of viral RNA was detected in nasal washes, and both deaths occurred in these groups of animals. However, no difference was seen in the overall mean lung titers and duration of illness.
All viruses tested in this study caused similar quality and quantity of pathology, and a significant amount of pathology was observed both in the upper and lower respiratory tract. Influenza viral antigen was detected throughout the respiratory tract, and disease was documented from the nasal cavity to the alveoli, again demonstrating the ability of both the wild-type and the resistant viruses to cause significant upper and lower respiratory tract disease.
The finding of bacteria in the lungs of the animal infected by contact transmission with virus Br that died on day 12 is interesting. This animal exhibited pathology consistent with a secondary bacterial pneumonia and hemothorax superimposed on the viral pathology pattern seen in the other ferrets. Studies of autopsies of victims of the 1918 influenza pandemic demonstrated that .95% of individuals who died did so with a secondary bacterial pneumonia [28] . Autopsy reports from the current H1N1 pandemic also confirm the significant role that secondary bacterial pneumonias play in deaths due to pandemic influenza A [29] . The majority of these secondary bacterial infections both today and during past pandemics are with bacterial species that commonly colonize the human upper respiratory tract, such as Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. The gram-positive bacteria that caused pneumonia in this ferret are consistent morphologically with Listeria monocytogenes, a known colonizer of ferrets that has been shown to cause secondary pulmonary disease when ferrets are infected with canine distemper virus [30] . This observation and the death of this ferret serve to reinforce the importance that a secondary bacterial pathogen can play in a significant underlying viral infection, in this case leading to mortality.
If we consider the duration of infection and shedding in the immunocompromised human hosts together with the clear transmission and pathogenesis of these viruses in the ferret model, the data demonstrate that pandemic H1N1 viruses can accommodate the NA H275Y mutation without attenuation or loss of transmissibility. This suggests that the selection for resistance to oseltamivir and peramivir can occur quickly and efficiently, and may be able to spread effectively in the population. The significant upper and lower respiratory tract pathology observed demonstrates that the rapid selection for multidrug resistance has no effect on the ability of the virus to replicate and cause disease and that, in the presence of a secondary bacterial pathogen, can lead to a fatal outcome.
These findings reinforce the significance of drug-resistant influenza A viruses and the need for new and alternative treatment strategies for influenza. Multidrug-resistant seasonal and pandemic viruses pose new problems that must be further investigated, including the mechanisms of resistance development, influenza treatment practices that lead to resistance, and the populations of patients, especially immunocompromised patients, in whom such resistant viruses may readily develop. Only through careful evaluation will we be able to develop better treatment and preventative strategies for both seasonal and pandemic influenza A, especially for those at high risk of severe disease or complicated infections.
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